What is it?
What phenibut is
1Phenibut is a synthetic analogue of gamma-aminobutyric acid (GABA), commonly described as beta-phenyl-GABA. It is psychoactive and is not a routine dietary nutrient or low-risk wellness supplement.
Evidence snapshot
6The strongest public-facing conclusion is not that phenibut improves cognition. The more defensible summary is that older/regional medical-use literature exists, while modern evidence for general nootropic performance is limited and safety concerns are well documented.
Names, aliases and forms
Mechanisms of action
GABA-B-related pharmacology
6Phenibut is structurally related to GABA and is commonly discussed in relation to GABA-B activity and central nervous system effects. This mechanistic framing helps explain sedation and dependence risk, but does not establish a cognitive-performance benefit.
Alpha-2-delta calcium-channel evidence
12R-phenibut has been reported to bind the alpha-2-delta subunit of voltage-dependent calcium channels and to show gabapentin-like effects in preclinical models. This supports a more precise pharmacology description, but it remains mechanistic/preclinical evidence rather than a consumer benefit claim.
Potential effects and evidence map
Phenibut should not be presented as a well-established cognitive enhancer. Human evidence for performance, memory, motivation, or everyday nootropic use is limited or indirect. Safety is more clearly documented through poison-center surveillance, product-analysis studies, pharmacology reviews, and case literature for intoxication, dependence, and withdrawal.
Phenibut has been studied and used in older/regional contexts for calming effects, but the evidence base is limited and should not be generalized to unsupervised supplement use.
Sleep-related use appears in older/regional literature, but modern supplement-use evidence is limited and the same sedative effects create impairment risk.
Mood or stress-related claims are not strongly established for consumer nootropic use; available human support is older, regional, and context-specific.
Anecdotal social-ease claims are common online, but reliable human evidence for this public-use claim is absent or too indirect.
There is no reliable evidence signal that phenibut supports focus or attention in healthy consumers.
Memory and learning claims are not supported by strong modern human evidence for consumer nootropic use.
Typical dosages and timing
WHO ECDD review material discusses a 250-750 mg/day range in regulated or research/medical contexts. This field is retained for evidence context only and is not an over-the-counter dosing recommendation.
Commercial product labels and online use patterns may not match clinical or reviewed contexts. Because dependence, withdrawal, and toxicity are documented, public copy should avoid optimization tips or escalation guidance.
Onset, duration and tolerance
WHO ECDD material reports limited pharmacokinetic information, including an approximate 5.3-hour The time for blood levels to fall by half during the final elimination phase.Source, while oral onset around 2-4 hours and subjective duration around 15-24 hours are described as recreational-user reports. Treat timing fields as approximate context, not instructions for repeat use.
Safety, side effects and risk profile
Sedation, lethargy, confusion, reduced consciousness, and coma are documented in poison-center and case literature.
Repeated use can be associated with tolerance, dependence, and withdrawal; systematic reviews describe severe presentations including agitation, hallucinations, delirium, and seizures.
Risk is elevated with alcohol and other CNS-active substances, including sedatives, anxiolytics, opioids, gabapentinoids, antipsychotics, anticonvulsants, and sleep aids.
The FDA states phenibut is not a dietary ingredient in the U.S.; products marketed as dietary supplements with phenibut are regulatory concerns.
Agitation and insomnia are reported particularly in withdrawal or adverse-use contexts.
Nausea and other gastrointestinal complaints appear in exposure and case literature.
Dizziness and neurologic symptoms are reported in poison-center and case literature.
Tachycardia and blood-pressure related concerns appear in exposure reports, especially in adverse-use contexts.
Pregnancy and lactation safety are not established; absence of data should be treated as a caution, not reassurance.
The nootropic benefit evidence is weaker than the safety signal, and product quality/dose-labeling concerns add uncertainty for consumer products.
CDC reported 1,320 phenibut exposure calls to U.S. poison centers during 2009-2019. Reported outcomes included drowsiness or lethargy, agitation, tachycardia, confusion, coma, major effects, and three deaths.
Repeated use can be associated with tolerance, dependence, and withdrawal. Review literature describes withdrawal presentations that may include agitation, insomnia, psychosis, delirium, hallucinations, and seizures.
Because sedation, confusion, and reduced consciousness are documented, phenibut should not be framed as compatible with driving, machinery operation, or other impairment-sensitive tasks.
Interactions and cautions
Risk is most relevant with alcohol and other CNS depressants or CNS-active drugs, including sleep aids, benzodiazepines, opioids, gabapentinoids, antipsychotics, anticonvulsants, and anxiolytics.
People using psychiatric, neurologic, pain, sleep, or seizure-related medications should not rely on public supplement content for phenibut decisions. Interaction and withdrawal management require qualified clinical guidance.
Legal and regulatory status
The FDA states that phenibut does not meet the definition of a dietary ingredient under the FD&C Act. Products labeled as dietary supplements that list phenibut as a dietary ingredient are considered misbranded.
CDC described phenibut as legal to possess in the U.S. but not approved by FDA for clinical use. Keep this separate from FDA dietary-supplement marketing status, and verify current federal, state, and local rules before making legal conclusions.
Phenibut has been used as a medicine in some countries, while consumer-product and controlled-substance status varies by jurisdiction. Treat legal status as country-specific and time-sensitive.
How it compares
Phenibut should not be grouped casually with lower-risk calming ingredients such as magnesium or L-theanine. Its psychoactive profile, withdrawal risk, and U.S. supplement-status issues make the comparison materially different.
Practical buying and quality notes
- In the U.S., phenibut is not a lawful dietary ingredient for dietary supplements according to FDA. Public buying copy should emphasize regulatory caution rather than purchase encouragement.2
- Products may list phenibut as a free amino acid or as a hydrochloride salt. Labels should identify the exact form and amount; do not assume equivalence when the form, assay, or purity testing is unclear.1
- Published product-analysis work found phenibut quantities in supplements before and after FDA warnings, supporting a conservative approach to label accuracy and third-party testing claims.9
FAQ
Is phenibut a dietary supplement in the U.S.?
2No. FDA states that phenibut does not meet the definition of a dietary ingredient under the FD&C Act, and products marketed as dietary supplements with phenibut as a dietary ingredient are considered misbranded.
What are the main safety concerns with phenibut?
4The main concerns are sedation and impairment, confusion or reduced consciousness in adverse exposures, tolerance, dependence, withdrawal, and interactions with alcohol or other CNS-active substances.
Does phenibut have strong nootropic evidence?
6No. Older/regional medical-use and pharmacology literature exists, but strong modern human evidence for general cognitive enhancement, focus, memory, or motivation in healthy consumers is not established.
Is the 250-750 mg/day range a recommendation?
11No. The range is included as reported research or regulated-medical context only. It should not be read as advice to use phenibut, repeat doses, or combine it with other substances.
References
- PubChem. Phenibut (CID 14113). National Library of Medicine.
- U.S. Food and Drug Administration. Phenibut in Dietary Supplements.
- U.S. Food and Drug Administration. FDA Acts on Dietary Supplements Containing DMHA and Phenibut. Content current as of 2019-04-29.
- Graves JM, Dilley JA, Kubsad S, Liebelt E. Notes from the Field: Phenibut Exposures Reported to Poison Centers - United States, 2009-2019. MMWR Morb Mortal Wkly Rep. 2020;69(35):1227-1228.
- McCabe DJ, Bangh SA, Arens AM, Cole JB. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med. 2019;37(11):2066-2071.
- Penzak SR, Bulloch M. Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal. J Clin Pharmacol. 2024;64(6):652-671.
- Weleff J, Akiki M, Singh A, Baronia R, Deolia S, Nasur E, Hadan TF, Sharma P. Clinical Presentations and Treatment of Phenibut Toxicity, Withdrawal, and Use Disorder: A Systematic Literature Review. J Addict Med. 2023;17(4):407-417.
- Stewart C, et al. A Systematic Review of Phenibut Withdrawals. Cureus. 2024;16(9):e68775.
- Cohen PA, Avula B, Katragunta K, Travis JC, Khan I. Quantity of phenibut in dietary supplements before and after FDA warnings. Clin Toxicol (Phila). 2022;60(4):486-488.
- Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev. 2001;7(4):471-481.
- World Health Organization Expert Committee on Drug Dependence. Phenibut: Critical Review Report. Forty-fourth meeting, 11-15 October 2021.
- Zvejniece L, Vavers E, Svalbe B, et al. R-phenibut binds to the alpha2-delta subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacol Biochem Behav. 2015;137:23-29.